Genolution

Genolution OCF Margin

The Operating Cash Flow Margin of Genolution (225220.KQ) as of Nov 11, 2026 is -74.56 %. In the previous year, Operating Cash Flow Margin was -20.08 % — a change of 271.33% (lower).

OCF Margin

-74.56 %

YoY

271.33%

Last updated:

Operating Cash Flow Margin of Genolution is 2025 -74.56 % . Operating Cash Flow Margin of Genolution was 2024 -20.08 % . It decreases by 271.33% lower compared to the previous year.

The Genolution OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
4.71 KRW
Jan 1, 2019
-2.04 KRW
Jan 1, 2020
53.89 KRW
Jan 1, 2021
35.33 KRW
Jan 1, 2022
35.58 KRW
Jan 1, 2023
-11.63 KRW
Jan 1, 2024
-20.08 KRW
Jan 1, 2025
-74.56 KRW
The Genolution OCF Margin history
YEAROCF MarginYoY
-74.56 %+271.33%
-20.08 %+72.60%
-11.63 %-132.69%
35.58 %+0.71%
35.33 %-34.44%
53.89 %-2,742.10%
-2.04 %-143.31%
4.71 %-83.98%
29.40 %-1,733.40%
-1.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Operating Cash Flow Margin of Genolution is -74.56 % in 2025.

Operating Cash Flow Margin of Genolution changed from -20.08 % to -74.56 %, representing a 271.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Genolution since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Genolution with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Genolution

All Key Metrics — Genolution